Tanyaporn Pattarabanjird1,2,3, Melissa Marshall1,2, Aditi Upadhye2, Prasad Srikakulapu1,2, James C Garmey1,2, Antony Haider1,2, Angela M Taylor4, Esther Lutgens5, Coleen A McNamara1,2,4. 1. Carter Immunology Center (T.P., M.M., P.S., J.C.G., A.H., C.A.M.), University of Virginia, Charlottesville. Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität, Munich, Germany. 2. Cardiovascular Research Center (T.P., M.M., A.U., P.S., J.C.G., A.H., C.A.M.), University of Virginia, Charlottesville. Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität, Munich, Germany. 3. Department of Biomedical Engineering (T.P.), University of Virginia, Charlottesville. Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität, Munich, Germany. 4. Division of Cardiovascular Medicine, Department of Medicine (A.M.T., C.A.M.), University of Virginia, Charlottesville. Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität, Munich, Germany. 5. German Centre for Cardiovascular Research, Partner Site Munich Heart Alliance, Germany (E.L.).
Abstract
BACKGROUND: B1a and B1b lymphocytes produce IgM that inactivates oxidation-specific epitopes (IgMOSE) on LDL (low-density lipoprotein) and protects against atherosclerosis. Loss of ID3 (inhibitor of differentiation 3) in B cells selectively promotes B1b but not B1a cell numbers, leading to higher IgMOSE production and reduction in atherosclerotic plaque formation. Yet, the mechanism underlying this regulation remains unexplored. METHODS: Bulk RNA sequencing was utilized to identify differentially expressed genes in B1a and B1b cells from Id3KO and Id3WT mice. CRISPR/Cas9 and lentiviral genome editing coupled with adoptive transfer were used to identify key Id3-dependent signaling pathways regulating B1b cell proliferation and the impact on atherosclerosis. Biospecimens from humans with advanced coronary artery disease imaging were analyzed to translate murine findings to human subjects with coronary artery disease. RESULTS: Through RNA sequencing, P62 was found to be enriched in Id3KO B1b cells. Further in vitro characterization reveals a novel role for P62 in mediating BAFF (B-cell activating factor)-induced B1b cell proliferation through interacting with TRAF6 (tumor necrosis factor receptor 6) and activating NF-κB (nuclear factor kappa B), leading to subsequent C-MYC (C-myelocytomatosis) upregulation. Promoter-reporter assays reveal that Id3 inhibits the E2A protein from activating the P62 promoter. Mice adoptively transferred with B1 cells overexpressing P62 exhibited an increase in B1b cell number and IgMOSE levels and were protected against atherosclerosis. Consistent with murine mechanistic findings, P62 expression in human B1 cells was significantly higher in subjects harboring a function-impairing single nucleotide polymorphism (SNP) at rs11574 position in the ID3 gene and directly correlated with plasma IgMOSE levels. CONCLUSIONS: This study unveils a novel role for P62 in driving BAFF-induced B1b cell proliferation and IgMOSE production to attenuate diet-induced atherosclerosis. Results identify a direct role for Id3 in antagonizing E2A from activating the p62 promoter. Moreover, analysis of putative human B1 cells also implicates these pathways in coronary artery disease subjects, suggesting P62 as a new immunomodulatory target for treating atherosclerosis.
BACKGROUND: B1a and B1b lymphocytes produce IgM that inactivates oxidation-specific epitopes (IgMOSE) on LDL (low-density lipoprotein) and protects against atherosclerosis. Loss of ID3 (inhibitor of differentiation 3) in B cells selectively promotes B1b but not B1a cell numbers, leading to higher IgMOSE production and reduction in atherosclerotic plaque formation. Yet, the mechanism underlying this regulation remains unexplored. METHODS: Bulk RNA sequencing was utilized to identify differentially expressed genes in B1a and B1b cells from Id3KO and Id3WT mice. CRISPR/Cas9 and lentiviral genome editing coupled with adoptive transfer were used to identify key Id3-dependent signaling pathways regulating B1b cell proliferation and the impact on atherosclerosis. Biospecimens from humans with advanced coronary artery disease imaging were analyzed to translate murine findings to human subjects with coronary artery disease. RESULTS: Through RNA sequencing, P62 was found to be enriched in Id3KO B1b cells. Further in vitro characterization reveals a novel role for P62 in mediating BAFF (B-cell activating factor)-induced B1b cell proliferation through interacting with TRAF6 (tumor necrosis factor receptor 6) and activating NF-κB (nuclear factor kappa B), leading to subsequent C-MYC (C-myelocytomatosis) upregulation. Promoter-reporter assays reveal that Id3 inhibits the E2A protein from activating the P62 promoter. Mice adoptively transferred with B1 cells overexpressing P62 exhibited an increase in B1b cell number and IgMOSE levels and were protected against atherosclerosis. Consistent with murine mechanistic findings, P62 expression in human B1 cells was significantly higher in subjects harboring a function-impairing single nucleotide polymorphism (SNP) at rs11574 position in the ID3 gene and directly correlated with plasma IgMOSE levels. CONCLUSIONS: This study unveils a novel role for P62 in driving BAFF-induced B1b cell proliferation and IgMOSE production to attenuate diet-induced atherosclerosis. Results identify a direct role for Id3 in antagonizing E2A from activating the p62 promoter. Moreover, analysis of putative human B1 cells also implicates these pathways in coronary artery disease subjects, suggesting P62 as a new immunomodulatory target for treating atherosclerosis.
Entities:
Keywords:
atherosclerosis; cardiovascular diseases; immunoglobulin M; inflammation; proliferation
Authors: Ayelet Gonen; Lotte F Hansen; William W Turner; Erica N Montano; Xuchu Que; Apaїs Rafia; Meng-Yun Chou; Philipp Wiesner; Dimitrios Tsiantoulas; Maripat Corr; Michael S VanNieuwenhze; Sotirios Tsimikas; Christoph J Binder; Joseph L Witztum; Karsten Hartvigsen Journal: J Lipid Res Date: 2014-08-20 Impact factor: 5.922
Authors: Amanda C Doran; Nahum Meller; Alexis Cutchins; Hamid Deliri; R Parker Slayton; Stephanie N Oldham; Jae B Kim; Susanna R Keller; Coleen A McNamara Journal: Circ Res Date: 2008-07-31 Impact factor: 17.367
Authors: Michael J Lipinski; Kirsti A Campbell; Son Q Duong; Thomas J Welch; James C Garmey; Amanda C Doran; Marcus D Skaflen; Stephanie N Oldham; Kimberly A Kelly; Coleen A McNamara Journal: Arterioscler Thromb Vasc Biol Date: 2012-10-04 Impact factor: 8.311
Authors: Tom T P Seijkens; Claudia M van Tiel; Pascal J H Kusters; Dorothee Atzler; Oliver Soehnlein; Barbara Zarzycka; Suzanne A B M Aarts; Marnix Lameijer; Marion J Gijbels; Linda Beckers; Myrthe den Toom; Bram Slütter; Johan Kuiper; Johan Duchene; Maria Aslani; Remco T A Megens; Cornelis van 't Veer; Gijs Kooij; Roy Schrijver; Marten A Hoeksema; Louis Boon; Francois Fay; Jun Tang; Samantha Baxter; Aldo Jongejan; Perry D Moerland; Gert Vriend; Boris Bleijlevens; Edward A Fisher; Raphael Duivenvoorden; Norbert Gerdes; Menno P J de Winther; Gerry A Nicolaes; Willem J M Mulder; Christian Weber; Esther Lutgens Journal: J Am Coll Cardiol Date: 2018-02-06 Impact factor: 24.094
Authors: Hamid Hosseini; Yi Li; Peter Kanellakis; Christopher Tay; Anh Cao; Edgar Liu; Karlheinz Peter; Peter Tipping; Ban-Hock Toh; Alex Bobik; Tin Kyaw Journal: J Am Heart Assoc Date: 2016-11-14 Impact factor: 5.501
Authors: Prasad Srikakulapu; Tanyaporn Pattarabanjird; Aditi Upadhye; Sai Vineela Bontha; Victoria Osinski; Melissa A Marshall; James Garmey; Justine Deroissart; Thomas A Prohaska; Joseph L Witztum; Christoph J Binder; Nichol E Holodick; Thomas L Rothstein; Coleen A McNamara Journal: Front Immunol Date: 2022-07-22 Impact factor: 8.786